|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Do different brands of oral contraceptives differ in their effects on |
| BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY. 1997 May;104(5):516- |
| In response to unpublished data revealing a doubling of venous thromboembolism risk with oral contraceptives (OCs) |
| containing desogestrel or gestodene compared with levonorgestrel, the UK Committee on Safety of Medicines |
| advised physicians that women taking these third-generation OCs should be switched to another formulation. There |
| are indications, however, that the studies on which this recommendation was based were flawed by prescriber bias |
| and confounding. In addition, laboratory measures of thrombosis and fibrinolysis do not indicate a shift toward a |
| thrombotic state associated with the newer progestogens. Moreover, desogestrel and gestodene OCs have been |
| associated with a reduced risk of arterial disease when compared to levonorgestrel-containing OCs. Since the |
| mortality associated with acute myocardial infarction is almost 50%, compared with 1-2% for venous |
| thromboembolism, this information should be considered when counseling OC users about their risk of |
| cardiovascular disease. Although the European Union Committee on Proprietary Medicinal Products has taken the |
| position that all OCs are contraindicated in women with current or past cardiovascular disease, unlike the UK |
| Committee, it has not made any specific recommendations about the suitability or non-suitability of the third- |
| generation OCs. (PubHealth.info Document ID: CONT2T 558-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "Do different brands of oral contraceptives differ in their |
| effects on cardiovascular disease?", is(are) Crook D. The source of this article is "BRITISH JOURNAL OF |
| OBSTETRICS AND GYNAECOLOGY. 1997 May;104(5):516-20.". This article was published in 1997 in English |
| language(s). (PubHealth.info® Document ID: CONT2T 558-06. All rights reserved with PubHealth.info) PIN: 5558 |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |